CSL, the pharmaceutical giant, has been indemnified by tax payers, against any lawsuits coming from the swine flu vaccine.

According to the Therapeutic Goods Administration CSL was indemnified as health authorities continue to look into the matter of discoloration which affected the national stockpile.

After US Food and Drug Administration hued and cried that CSL had deviated from requirements needed for goods manufacturing the TGA began its investigation of the swine flu stockpile.

According to a TGA spokeswoman for the pandemic flu vaccine there are indemnity arrangements, similar to all pandemic flu vaccine arrangements around the world, and by nature these are commercial. .The previous government had agreed to it when the contract for the purchase was put in train.

In the last year, CSL was given in the tune of nine million dollars by the Rudd government for conducting clinical trials of the Panvax vaccine. After the trials the government asked the company to deliver twenty one million doses of that vaccine to New Zealand, worth one hundred and thirty one million dollar.

The indemnity had been termed as a liability of contingent which could not be quantified and listed in the federal budget.

There are certain indemnities provided under certain conditions to manufacturers of pandemic and pre-pandemic influenza vaccines for supply or for supply in the future.

According to the TGA website Panvax can be termed as an effective and safe vaccine for the prevention of H1N1 swine flu.

There were one thousand seven hundred and seventy three side effects reported out of the nine million doses of Panvax and Panvax junior administered for the first time.

All the side effects had been mild and in the kind of headache gastro intestinal upset, swelling, soreness etc, and nothing serious.